NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

IRIDEX Corporation (IRIX) Stock Analysis

IRIDEX Corporation (IRIX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

IRIX

$0.70

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IRIX with… →

IRIX Key Statistics

As of Sep 4, 2026
Trading
Open
$0.70
Previous Close
$0.70
Day's Range
0.69–0.72
52-Week Range
0.69–1.65
Volume
73.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.63
Valuation
Market Cap
$12.18M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.94
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.20
Financials (FY)
Revenue (FY)
$52.68M+8.23%
Net Income (FY)
−$4.44M
Profit marginThe share of revenue left as profit after all costs and taxes.
−6.88%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
17.41M
1-Year Return
−46.97%
Dividend and dates
Earnings Date
November 17, 2026
Avg Volume
66.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IRIX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−38.60%
2025−32.14%
2024−40.21%
2023+39.80%
2022−67.10%
2021+143.43%
2020+12.56%
2019−52.55%
2018−38.32%
2017−45.80%
2016 (partial year)−5.95%

As of September 4, 2026.

IRIX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$52.68M−$4.44M−8.4%
2024$48.67M−$8.91M−18.3%
2023$51.87M−$9.57M−18.5%
2022$56.97M−$7.55M−13.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$52.68M$19.23M−$2.57M−$4.44M−8.4%
2024$48.67M$19.50M−$8.30M−$8.91M−18.3%
2023$51.87M$21.81M−$10.01M−$9.57M−18.5%
2022$56.97M$25.37M−$7.54M−$7.55M−13.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IRIX Valuation vs Medical Devices Median

Median of 151 stocks
MetricIRIXMedical Devices medianvs median
P/S ratio0.242.980.1x the median
Profit margin−6.88%−1.69%5.2 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values IRIDEX Corporation (IRIX) at $12.18M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 93.

IRIX last closed at $0.70 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $0.69 to $1.65. The latest close sits 1.3% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $52.68M. Against the prior fiscal year total of $48.67M, that is a change of +8.23%. The same year closed with a net loss of $4.44M. The reported profit margin is −6.88%. That is 5.2 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −0.2.

Across the 4 fiscal years on file, revenue moves from $56.97M in 2022 to $52.68M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.94. Measured against sales, the shares trade at 0.24 times revenue. On price-to-sales that is 0.1 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.63. Annualized volatility over the trailing 10 years is 71.62%. The trailing one-year price return is −46.97%. Measured over 10 years, that is −26.29% a year compounded.

Growth & Income

No dividend is on file for IRIX.

So far in 2026 the price is −38.60%. Across the complete calendar years on file, 2021 returned +143.43% and 2022 returned −67.10%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

IRIDEX Corporation (IRIX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IRIDEX Corporation IRIX $12.18M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. IRIDEX Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Visit website →